Relay Therapeutics Inc (RLAY) is a Healthcare · Biotechnology company listed on NASDAQ. Price $18.84 (-1.82%), Market cap $2.34B, 52-week low–high $2.85 ~ $16.80.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and aGal chaperone for Fabry diseases. It also develops RLY-8161, an oncogene driver that belongs to the RAS family of signaling proteins. In addition, the company develops lirafugratinib (RLY-4008), a recep
Financial statements, price targets, institutional (13F) holdings and related news for Relay Therapeutics Inc are updated in real time on BlackAll Trade.
Relay Therapeutics Inc trades at $18.84 (-1.82%). Real-time quotes and charts are available on BlackAll Trade.
Relay Therapeutics Inc has a market cap of about $2.34B.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted o